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Abstract
Background: Adequate surgery still remains the only curative treatment of chordoma. Interesting clinical data on
advanced disease with molecularly targeted therapies were reported.
Methods: We described the clinical outcome of a series of chordoma patients followed at Regina Elena National
Cancer Centre of Rome from 2004 to 2008.
Results: Twenty-five consecutive patients with sacral (11 patients), spine (13 patients), and skull base (1 patient)
chordoma went to our observation. Six patients (24%) had primary disease, 14(56%) a recurrent disease, and 5(20%)
a metastatic spreading. Surgery was the primary option for treatment in 22 out of 25 patients. Surgical margins
were wide in 5 (23%) and intralesional in 17(77%) patients; 3 out of 4 in-house treated patients obtained wide
margins. After first surgery, radiotherapy (protons or high-energy photons) were delivered to 3 patients. One out of
the 5 patients with wide margins is still without evidence of disease at 20 months from surgery; 2 patients died
without evidence of disease after 3 and 36 months from surgery. Sixteen out of 17 (94%) patients with intralesional
margins underwent local progression at a median time of 18 months with a 2-year local progression-free survival
of 47%. The 5-year metastasis-free survival rate was 78.3%. Seventeen patients with locally advanced and/or
metastatic disease expressing platelet-derived growth factor receptor (PDGFR) b were treated with imatinib
mesylate. A RECIST stabilization of the disease was the best response observed in all treated cases. Pain relief with
reduction in analgesics use was obtained in 6 out of 11 (54%) symptomatic patients. The 5- and 10-year survival
rates of the entire series of patients were 76.7 and 59.7%, respectively.
Conclusions: Despite progress of surgical techniques and the results obtained with targeted therapy, more effort
is needed for better disease control. Specific experience of the multidisciplinar therapeutic team is, however,
essential to succeed in improving patients’ outcome.
Background
Chordoma is a rare, low-grade, primary malignant bone
tumour arising from primitive notochord remnants of
the axial skeleton. It accounts for 1-4% of all primary
skeletal tumors and its incidence rate is inferior to 0.1
per 100,000 inhabitants per year [1,2].
Due to its ectodermal origin, chordoma is not prop-
erly a sarcoma even if it has clinically retained and clas-
sified as such being a primary tumor of bone [3]. The
sacrum represents the more common anatomical site of
origin accounting for 50-60% of all cases followed by
the skull base region (spheno-occipital/nasal) (25-35% of
cases), the cervical vertebrae (approximately 10% of
cases), and the thoracolumbar vertebrae (approximately
5% of cases) [4]. Chordoma biological behaviour is char-
acterized by a generally slow aggressive local growth
with a low to late tendency in metastatizing to distant
sites including the lung, bone, soft tissue, lymph nodes,
liver, and skin [4]. Although it is considered to be of
low metastatic potential, up to 40-60% of patients are,
however, reported to develop distant metastases over
the course of their disease [5-7].
Adequate wide surgery still remains the cornerstone of
chordoma treatment even though safe margins are often
hard to obtain because of its anatomical sites of origin.
The achievement of negative surgical margins favourably
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[8-10].
Conventional radiotherapy with high-energy photons
is poorly active and need, moreover, to be delivered in
d o s e sa sh i g ha s6 0 - 6 5G y[ 11]. It may offer some tem-
porary benefit in disease control in patients with inade-
quate surgery (i.e. close or positive margins) or, as
exclusive treatment, in patients with unresectable/inop-
erable disease. Proton radiotherapy may succeed in
offering better tumour control and fewer side effects
even if it still not readily available in comparison to
external-beam radiotherapy [12].
Sensitivity to chemotherapy is very low and generally
reported in the small subgroup of patients with high-
grade dedifferentiated chordomas with agents active in
high-grade sarcomas [13]. Chordoma overexpresses pla-
telet-derived growth factor receptor (PDGFR)-b and its
phosphorylated form, denoting constitutive activation
[14]. A phase II trial with tyrosine kinase inhibitor ima-
tinib meyslate (IM) at 800 mg daily dose in 55 patients
with unresectable or metastatic chordomas, showed a
clinical benefit rate (complete response plus partial
response plus stable disease ≥ 6m o n t h s )o f7 3 %w i t ha
38% of patients free from progression at 1 year [15].
Subjective pain relief was reported by 64% of 39 symp-
tomatic patients. Other molecularly target agents (cetux-
imab, gefitinib) and antiangiogenic therapy with
thalidomide were tested in single cases of chordomas
with interesting results [16,17].
In this report, we present an analysis of the clinical
characteristics, multidisciplinary treatment and prog-
nosis of 25 consecutive patients with chordoma
observed at our cancer centre from February 2004 until
December 2008.
Methods
Patient Population
Apart from some isolated cases needing surgical treat-
ment over the years, a systematic multidisciplinary clini-
cal approach to patients affected by chordoma began at
Regina Elena National Cancer Institute of Rome (Italy)
together with the Department of Orthopedic Surgery in
2004. Our study focused on 25 consecutive cases
observed between February 2004 and December 2008
and followed by the same team of specialists (orthopedic
surgeons, medical oncologists, radiotherapists, patholo-
gists, and radiologists) particularly dedicated to the
management of bone/soft tissue sarcomas.
Medical charts were consulted to obtain the following
d a t a :s e x ,a g e ,p r e v i o u sc l i n i c a lh i s t o r y ,t y p eo fs u r g e r y
with a description of techniques performed at our cen-
tre, type of radiotherapy, medical treatments (che-
motherapy, targeted agents), functional outcome and
pain control. Seven out of the 25 patients of our case
series were enrolled onto a prospective multicenter
phase II study [15] with IM and 9 others patients were
given the drug within an expanded access protocol to
the use of IM. Both studies were approved by the local
Ethical Committee of our Cancer Institute and written
informed consent was obtained from all the patients
who participated to the clinical trials. Retrospective
chart review was approved by the institutional review
board of the Regina Elena Cancer Institute.
Surgical Procedures
In our centre primary surgery was performed in two
separate operations. The first surgery entailed using an
anterior approach by isolating the neurovascular bundles
and dissecting them from the anterior part of the mass.
The second operation involved a resection and mass
excision adopting a posterior approach [18,19]. During
the first approach, a Gore-Tex® mesh is put between the
neurovascular bundles and the anterior part of the mass
to decrease the risk of adhesion during the second
operation. A period of time of 2-3 weeks elapsed
between the first and second approach in order to allow
patient’s recovery.
Biological Assessments
Due to the possibility to treat PDGFR-b positive locally
advanced, inoperable or metastatic patients with IM in
the context of a prospective phase II clinical trial [15]
and a subsequent expanded access protocol, immunohis-
tochemical determination of PDGFR-b,t o g e t h e rw i t h
PDGFR-a and c-kit, were performed at our Department
of Pathology. The tumor samples of three patients that
were found PDGFR-b negative at immunohistochemis-
try, were then referred to the Department of Pathology
of National Cancer Institute of Milan (Italy) for deter-
mining the presence of PDGFR-b ligand. Written
informed consent was obtained from all the patients
enrolled onto the clinical trials with IM.
Statistical Analysis
The patients who were followed up at our centre were
planned to undergo a MRI/CT scan of the primitive site
every 3 months for the first 2 years, every 6 months for
the following 3 years and then every year from then
onwards. A chest X-ray/CT scan and abdomen-pelvis
US/CT scan were performed every 6 months while a
bone scan was planned every 1 year.
For those patients who were operated with wide mar-
gins (WM), the time elapsed from primary surgery to
instrumental documentation of local relapse was
referred to as time to local recurrence. For patients with
intralesional margins (ILM), the time from primary sur-
gery to clinical/instrumental documentation of local
progression of disease was defined as time to local pro-
gression. Time to distant metastases was calculated
from the time of first diagnosis of the chordoma to doc-
umentation of disease at any distant site. Overall
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to the time of death for any cause. Overall and disease-
free survival were calculated by the Kaplan-Meier
method.
Results
Patients and disease characteristics
From February 2004 to December 2008, 25 patients with
various stage of disease were referred to our cancer
institute (Table 1). Eighteen patients were males and 7
patients were females. The median age at diagnosis was
62 years old (range: 40-77 years old). The site of origin
of chordoma was the sacrum in 11 patients, the spine in
13 patients (10 localized in the lumbar spine, 2 in cervi-
cal and 1 in thoracic spine), and the skull base in 1
patient. At the time of our first observation, 6 patients
(24%) had primary disease, 14 patients (56%) had local
residual/recurrent disease, three (12%) patients had
developed distant metastases after local relapse and two
patients (8%) had only metastatic lesions.
Pain and neurological impairment were the most com-
mon pre-diagnosis symptoms.
Surgery
Primary surgery was performed in 22 out of 25 patients.
Three patients underwent only to diagnostic biopsy. Spe-
cifically, one patient with a sacrum localization was con-
sidered resectable but inoperable due to age (74 years
old), one other patient was not operated on for local
extension of the disease, and the last one died for bad
general health conditions after a peritonitis following the
first surgical time for anterior vascular bundles isolation.
At the time of primary surgery, WM and ILM were
obtained in 5 (23%) and 17 (77%) patients, respectively.
Four patients, all affected by sacral chordoma, were pri-
marily treated at our cancer centre obtaining WM in
three of them. The most frequent complication for in-
house patients was the posterior wound dehiscence,
occurring in three patients. The occurrence of deep
venous thrombo-embolism and cerebral haemorrhage
led to one patient’s death without evidence of disease
after three months from surgery.
Radiotherapy
Eleven patients (44%) underwent to radiotherapy. Com-
plementary conventional and proton radiotherapy were
Table 1 Patient characteristics at first observation.
Patient characteristics No. (%)
Total number 25
Gender Male 18 (72)
Female 7 (18)
Age (years) Median: 62
Range: 40-77
Primary tumor site Sacrum 11(44)
Spine 13(52)
Skull base 1 (4)
Extension of disease Primary disease 6 (24)
Local residual/recurrent disease 14 (56)
Metastasis 5 (20)
Treatments Primary surgery
22 (88)
Wide margins 5 (23)
Intralesional margins 17 (77)
Surgery for recurrent disease 13 (52)
Radiotherapy
11 (44)
Adjuvant 3 (27)
Palliative 8 (73)
Target therapy
16 (64)
imatinib meysilate 16
nilotinib 1
sirolimus 1
Chemotherapy plus target therapy 1
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mary surgery, respectively. Palliative radiotherapy (con-
ventional or stereotactic) was carried out in eight
patients.
Medical treatments
The immunohistochemical (IHC) analysis for PDGFR-b
was obtained from 19 patients and 16 of them tested
positive. Paraffin-embedded blocks of the three nega-
tive patients were referred to the Department of
Pathology of National Cancer Institute of Milan (Italy)
for determining the presence of PDGFR-b cognate
ligand that resulted positive. The IHC analysis for
PDGFR-a turned out positive in 6 out of 9 and c-kit
in 3 out of 9 tested patients, respectively. Sixteen
patients with non resectable/inoperable or metastatic
PDGFR b expressing disease were treated at our centre
with IM in the context of both a phase II prospective
clinical trial (7 patients) and a subsequent expanded
access protocol (9 patients). One patient with locally
unresectable recurrence was treated with IM in an
external centre. Treatment is still ongoing in 6
patients. A RECIST stabilization of the disease was the
best response observed in all treated cases. Pain relief
with reduction in analgesics use was obtained in 6 out
of 11 (54%) symptomatic patients. A metabolic
response, expressed as a standard uptake value (SUV)
decrease at total body [F-18]-fluorodeoxy-D-glucose
positron emission tomography (FDG PET) scan, was
observed in 2 out 10 evaluable patients. The FDG PET
scan images documenting the metabolic response of
one patient are illustrated in Figure 1. The full dose of
800 mg daily was poorly tolerated for long periods and
the majority of patients underwent a dose reduction to
400-600 mg daily. Most common dose-limiting side
effects were fluid retention, gastroenteric/renal toxicity,
and skin reactions.
After progression on IM therapy, one patient received
weekly cisplatin in combination with IM and another
patient entered a second-line experimental protocol with
the tyrosine kinase inhibitor nilotinb (AMN 107) outside
of our centre. One patient was treated with IM and, sub-
sequently, with the mammalian target of rapamycin
(mTOR) inhibitor sirolimus in the context of clinical
trials outside of our institution. In table 2 are indicated
the medical treatments received by the patients and the
corresponding settings of disease.
Local relapse and metastases
The median follow up interval was 48 months (range: 2-
150). One out of the 5 patients with WM is still without
evidence of disease at 20 months from surgery. As far as
the remaining four patients, two died without evidence
of disease after 3 and 36 months from surgery, one
developed a distant metastatic disease without local
recurrence after 90 months, and the last one developed
a local and distant relapse of disease at 6 months from
surgery.
Sixteen out of 17 (94%) patients with ILM underwent
a first local progression of disease after a median time
of 18 months from primary surgery. The 2-year progres-
sion-free survival of this sub-group was 47%. Only one
patient with intralesional surgery is actually without
radiological evidence of local progression at 7 months
from resection.
Taking into account all surgically treated patients
(WM plus ILM), the median time to first evidence of
local recurrence/local progression of disease was 26
months with a 2-year local progression-free survival of
53% (Figure 2).
The median number of local relapses per patient was
1 (range:1-3). All local relapses were treated with sur-
gery, except for three cases treated exclusively with
radiotherapy. Currently, seven patients (28%) have devel-
o p e dam e t a s t a t i cd i s e a s ea tam e d i a nt i m eo f8 1
months from first diagnosis of chordoma. The 5-year
distant metastasis free survival was 78.3%. Sites of meta-
static involvement were lung (3 patients), bone (3
patients), soft tissues (3 patients), and liver (1 patient).
Survival
The 5-year and 10-year survival rate of the entire series
was 76.7% and 59.7%, respectively (Figure 3). The med-
ian overall survival was not reached. Two patients oper-
ated with wide margins died without evidence of disease
due to late surgical complications and general health
status deterioration after 3 and 36 months from surgery,
respectively. In table 3 is reported the clinical outcome
of the 25 patients of our case series according to pri-
mary local treatment.
Discussion
Chordomas account for less than 5% of all bone
tumours and its histological assessment is often delayed
due to non-typical signs and symptoms of disease with a
frequent clinical diagnosis of pelvic or vertebral and
irradiated pain due to discogenic or aspecific pathology.
The slow modality of biologic growth, associated to a
relatively low incidence of metastatic spread makes sur-
gery the primary treatment of this rare bone tumour.
Although potentially curative, a margin-free “en bloc”
resection is often very hard to obtain due to the anato-
mical sites of origin of chordom a ,i . e .s k u l lb a s e ,s p i n e ,
and sacrum. Moreover, surgery is often performed in
not referred centres, sometimes without a pre-surgical
specific histological diagnosis and without having any
technical expertise to perform a wide resection. The
extension of margins is, in fact, a very important prog-
nostic factor being correlated with the incidence of local
relapses and overall survival.
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(Italy) on 52 patients treated over a period of fifty years
until 2002, only 20% of patients operated on with safe
margins had a local recurrence with a relapse-free-survi-
val of 56-94 months [8]. This percentage has grown up
to 100% of patients who underwent radiotherapy alone
or inadequate surgery with ILM with the detection of a
local recurrence within 17-20 months from primary
surgery.
The central role of adequate radical surgery to assure
long term disease control has been, moreover, shown by
Tzortzidis et al in a recent series of 74 patients with pri-
mary or recurrent cranial base chordomas [9]. Recur-
rence-free survival at 10 years was 31% for the whole
g r o u po fp a t i e n t s ,b u tw a s4 2 %f o rt h ep r i m a r i l y
operated patients with aggressive microsurgical resection
and 26% for the reoperation cases (p = .0001).
In the retrospective analysis of Bergh et al on 39
patients with chordoma of the sacrum and mobile spine,
only 4 out of 23 patients (17%) in whom WM could be
obtained, developed local relapse in contrast with 13 out
of 16 patients (81%) with inadequate surgery [20]. Local
recurrence was significantly associated with an increased
risk of metastasis and tumour-related death (p < .001).
The adequacy of the final surgical resection was, how-
ever, not found to be related to the rate of metastases
being essentially the same (approximately 30%) for those
patients with WM as for those with intralesional or
marginal excision. In the multivariate analysis, the Cox
forward step wise model revealed that the performance
Table 2 Systemic treatments and setting of disease.
Treatment No Locally inoperable disease Metastatic disease
CT only - - -
IM (I
st line) 14 11 3
IM (I
st line) + IM/CT (II
nd line) 1 1 -
IM (I
st line) + Nilotinib (II
nd line) 1 - 1
IM (I
stline) + IM/Sirolimus(II
nd line) 1 - 1
CT: chemotherapy; IM: imatinib mesylate.
Figure 1 Metabolic response of one patient treated with imatinib mesylate. Comparison of FDG PET imaging pre- (a, b) and post- (c, d)
three months of therapy.
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centre was an independent prognostic factor for local
r e c u r r e n c ea n dm e t a s t a s i sw h i l ei n a d e q u a t es u r g i c a l
margins was an independent adverse prognostic factor
for local recurrence and tumour-related death. Other
independent adverse prognostic factors were micro-
scopic tumour necrosis for local recurrence, ki-67>5%
for metastases and larger tumour size for tumour-
related death, respectively.
In our series of 25 patients, 22 were submitted to sur-
gery on primary lesion between 1995 and 2008 (4
patients in our cancer centre from 2004). Initial WM
surgery were obtained in 5 patients while ILM were a
result in the remaining 17 patients. One out of the 5
patients with wide resection margins is still without evi-
dence of disease at 20 months while two patients died
without evidence of disease after 3 and 36 months from
surgery. The remaining two patients developed a distant
metastatic disease without local recurrence after 90
months and a local and distant relapse of disease at 6
months from surgery, respectively. At a median follow
up time of 48 months, almost all patients (16 out of 17,
94%) with not safe surgery (ILM) underwent first local
progression of disease after a median time of 18 months.
Only one patient with intralesional resection is currently
without radiological and clinical evidence of local pro-
gression but the post-surgical follow up is still short (7
months). Taking into account all surgically treated
patients, the median time to first evidence of local
recurrence/local progression of disease was 26 months
with a 2-year local progression-free survival of 53%. The
median number of total local relapses per patient was 1
(range:1-3) and surgery was the treatment of choice in
all cases except for three, the ones treated exclusively
with radiotherapy.
Conventional photon beam radiation therapy is scar-
cely active and needs, moreover, to be delivered in high
and often relatively toxic doses (60-65 Gy) to obtain a
curative effect [21]. It may have a role as a complemen-
tary treatment in patients with close or intralesional
margins or as definitive therapy in unresectable patients,
even if a local control at 5 years can be obtained in
much less than 50% of patients [6,22,23]. More recently,
the introduction of new techniques such as intensity
modulated radiation therapy (IMRT) and stereo-tactic
radio-surgery has led to the possibility to deliver high
photons doses with sparing surrounding tissue resulting
in improving treatment tolerability [24,25]. With the
intent to offer better tumour control and fewer side
effects, hadrons such as protons or charged particles
(carbon ions, helium or neon) were employed with
interesting clinical results [26,27]. In particular, pub-
lished series of high-dose protons radiotherapy showed
a 5-year control rate of 50-60% even if this approach is
still poorly available respect to external-beam radiother-
apy [28,29].
Only three out of 22 operated patients of our series
were treated with “complementary” radiotherapy (pro-
tons for two patients and conventional radiotherapy for
one patient) after primary surgery. All three patients
Figure 2 Local progression-free survival of all surgically treated
chordoma patients.
Figure 3 Overall survival of the entire series of 25 chordoma
patients.
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disease (two local and one at distance).
In our survey, seven patients (28%) developed a meta-
static disease at a median time from first diagnosis of 81
months. Five out of these seven patients obtained ILM
at first surgery and all of them developed metastatic dis-
ease after local relapse. One of the remaining two
patients with WM developed exclusive metastatic dis-
ease and the other one metastatic disease after local
relapse. The lung, bone and soft tissues were the most
frequent distant localizations. Patients with unresectable
disease (or resectable disease but through highly muti-
lating surgery) as well as patients with metastatic
spreading can be offered poor therapeutic chance of
cure or, at least, of tumour growth control. As for other
low-grade neoplasms, sensitivity to chemotherapy is very
low and generally reported in the very small subgroup
of patients with high-grade dedifferentiated chordomas
with agents active in sarcomas [13]. A prospective phase
II trial with topoisomerase I inhibitor 9-nitro-camp-
tothecin was conducted by Chugh et al with only one
(7%) objective response in 15 chordoma patients and a
median progression-free survival of 47% and 33% at 3
and 6 months, respectively [30]. Single case experiences
of responses to vinka alkaloids and alkylating agents
have been reported as well as to thalidomide, an antian-
giogenetic agent [17,31,32].
The advent of target therapy era has opened new per-
spectives for this rare and chemo-resistant disease. IM at a
daily dose of 800 mg was employed in 6 patients with a
prevalent non-dimensional tissue response (as evidenced
by characteristics CT and RMN pictures) but a sympto-
matic improvement and a cytological evidence of regres-
sive type alterations and apoptotic figures [33].
Successively, in a molecular/biochemical analyses of the
three receptors targeted by IM (PDGFRB, PDGFRA, and
KIT) in a series of 31 chordoma patients, it was proven
that PDGFRB was highly expressed and phosphorilated
whereas PDGFRA and KIT were less expressed but equally
activated [14]. These results, together with the absence of
gain-of-function mutationsa n dt h ep r e s e n c eo fc o g n a t e
ligands, strongly supported the hypothesis that the activa-
tion mechanism is the autocrine/paracrine loop.
The clinical activity of IM at 800 mg daily dose was
explored in a recent multicenter phase II prospective
trial on 55 (7 of whom included in the present series)
patients with locally advanced or metastatic chordomas
with biomolecular or immunohistochemical evidence of
PDGFRb activation and/or presence of PDGFB [15]. A
clinical benefit rate (complete response plus partial
response plus stable disease ≥ 6 months) was obtained
in 71% of 44 evaluable patients. The median progres-
sion-free survival was 39 weeks and 35% of patients
were free from progression at 1 year. Interestingly, a
subjective pain relief was reported by 64% of 39 sympto-
matic patients. A synergy between IM and cisplatin was,
furthermore, assumed by the evidence of a restoration
of response to the tyrosine-kinase inhibitor with adding
a low dose of the cytotoxic agent [34].
Also, in the present case series, over 50% of patients
experienced symptomatologic pain improvement with
reducting the use of analgesics during IM treatment.
The full dose of 800 mg daily was poorly tolerated for
long periods and the majority of patients underwent a
dose reduction to 400-600 mg daily.
As for other solid tumours, most chordomas strongly
express epidermal growth factor receptor (EGFR) and
the hepatocyte growth factor/scatter factor receptor c-
Met and some promising responses to molecularly tar-
get agents such as cetuximab and gefitinib were
described [16,35]. The evidence of AKT activation in a
small subgroup of patients has, moreover, led to test the
adjunctive administration of the mammalian target of
rapamycin (mTOR) inhibitor sirolimus to patients with
secondary IM resistant chordomas demonstrating a re-
establishment of tumour response [36]. In table 4 are
summarized the results of recent retrospective and pro-
spective studies on chordoma patients demonstrating a
growing interest for integration of locoregional
approaches (surgery and radiotherapy) with systemic
treatments like above all targeted agents, especially in
Table 3 Clinical outcome according to primary local treatment of 25 chordoma patients.
Treatment No. Local P or R Distant metastases NED* AWD* Dead*
Wide S alone 5 1 2 1 (20) 1 (11) 3 (2 NED)
(3-123)
Intralesional S alone 14 13 2 1 (8) 9 (4-123) 4 (26-149)
Wide S+RT - - - - - -
Intralesional S+RT 3 3 2 - 2 (102-130) 1 (62)
Diagnostic biopsy only 3 1 1 2 (6-63) 1 (2)
RT alone - - - - - -
* months (range)
S: surgery; RT: radiotherapy: P: progression; R: recurrence; NED: not evidence of disease; AWD: alive with disease.
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survival is reported to be less than one year [5,7,10,20]
Conclusions
To conclude, despite the progress of current surgical
techniques and some encouraging results with the use
of targeted therapy, disease control and long-term
patients prognosis are still poor and chordoma results,
generally, in a long-lasting life-affecting disease. Never-
theless, specific experience of the multidisciplinary team
(surgeons, medical oncologists, radiotherapists, patholo-
gists, radiologists) is a very important pre-requisite in
succeeding to improve patients’ quality of life and, hope-
fully, outcome.
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Table 4 Recent published chordoma retrospective and prospective studies with multidisciplinary approach.
Author
(year)
No. of
patients
Surgery
(margins)
Radiotherapy Chemotherapy
(regimen)
Target
therapy
Comments/Conclusions
Azzarelli A.
(1988)[32]
33 21
(8WM;13 IL/
M)
7 adjuvant
4 palliative on
primary
Pallliative on
recurrences
1 (PVB)
1 (meclorethamine)
1
(cyclophosphamide)
1 (doxorubicin +
imidazolcarboximide)
- Short complete remission only after PVB.
5-, 10-, and 14-year OS rates of 30%, 10%, and 10%.
Bergh P.
(2000) [20]
39 39(23WM;16
IL/M)
5 adjuvant
14 palliative
- - 5-, 10-, and 20-year OS rates of 84%, 64%, and 52%.
Local recurrence significantly associated with an
increased risk of metastasis and tumor-related
death (p < .001)
Baratti D.
(2002) [10]
28 28(11WM;13
M; 4IL)
10 adjuvant
2 palliative
2 (not specified) - 5- and 10-year OS and DFS rates of 87.8 and 48.9%,
and 60.6 and 24.2%.
Boriani S.
(2006) [8]
48 48(18WM;20
IL; 10
palliative)
28 adjuvant
23 palliative
- 1 (IM) Only margin-free en-bloc resection associated with
long CDF survival.
No tumoral volume increase at 1 year from IM
onset in 1 patient.
Chug R.
(2005) [30]
15 12
(not
specified)
13 15 (9-NC) - Advanced disease.
1 PR (7%) with 9-NC lasting at least 8 months and
14 SD. Median TTP 9.9 months. 3- and 6-month
PFS rate of 47 and 33%.
Stacchiotti
S. (2007)
[15]
55 50 (not
specified)
39 6 (not specified) 55(IM) Advanced disease.
Clinical benefit (CR+PR+SD> 6 months) with IM:
71%. Median PFS: 9 months; 1-year PFS rate:
35%.;1-year OS rate: 80%.
Casali P.G.
(2007) [34]
6 n.a n.a n.a 6(IM + P post
prior IM)
Advanced disease.
4/6 re-establishment of response with P added to
IM.
Stacchiotti
S. (2009)
[36]
10 10 (not
specified)
6 - 10 (IM+
sirolimus post
prior IM+/-P)
Advanced disease. Clinical benefit with IM
+sirolimus: 89%. 4 patients on treatment for > 12
months
Ferraresi V.
(present
series)
25 22 (5
WM;17IL)
3 adjuvant
8 palliative
- 17 (IM)
1 (nilotinib)
1 (IM
+sirolimus)
1 (IM+P)
5- and 10-year survival
rate of 76.7 and 59.7%. 2-year local PFS rate: 53%.
5-year distant metastasis free survival: 78.3%.
WM: wide margins; IL: intralesional margins; M: marginal margins; PVB: cisplatinum/vinblastine/bleomycin; OS: overall survival; DFS: disease-free survival; IM:
imatinib mesylate; CDF: continuously disease free; 9-NC: 9-nitro-camptothecin; PR: partial response; SD: stable disease; TTP: time to progression; PFS: progression-
free survival; CR: complete response; P: cisplatinum.
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